AU Patent

AU2017202619A1 — Novel tricyclic compounds

Assigned to AbbVie Inc · Expires 2017-05-11 · 9y expired

What this patent protects

NOVEL TRICYCLIC COMPOUNDS The invention provides a compound of Formula (I) U-x R2 Formula (1) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention a…

USPTO Abstract

NOVEL TRICYCLIC COMPOUNDS The invention provides a compound of Formula (I) U-x R2 Formula (1) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017202619A1
Jurisdiction
AU
Classification
—
Expires
2017-05-11
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.